Leland Gershell Analyst Performance

Managing Director at Oppenheimer

Leland Gershell is a stock analyst at Oppenheimer in the medical sector, covering 40 publicly traded companies. Over the past year, Leland Gershell has issued 20 stock ratings, including and buy recommendations. While full access to Leland Gershell's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Leland Gershell's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 126 Last 7 Years
Buy Recommendations: 86.07% 105 Buy Ratings
Companies Covered: 40 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	86.1%	105 ratings
Hold	12.3%	15 ratings
Sell	1.6%	2 ratings

Out of 122 total stock ratings issued by Leland Gershell at Oppenheimer, the majority (86.1%) have been Buy recommendations, followed by 12.3% Hold and 1.6% Sell.

Best & Worst Calls

Best Call
0000.0%
EPZM
Jan 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
CRXTQ
Sep 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	97.5% of companies on NASDAQ	39 companies
OTCMKTS	2.5% of companies on OTCMKTS	1 company

Leland Gershell, an analyst at Oppenheimer, currently covers 40 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 40 companies	100.0%

Leland Gershell of Oppenheimer specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 16 companies	40.0%
PHARMACEUTICAL PREPARATIONS 11 companies	27.5%
MED - DRUGS 9 companies	22.5%
MED PRODUCTS 2 companies	5.0%
MED - GENERIC DRG 1 company	2.5%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	2.5%

About Leland Gershell

Leland Gershell is a Managing Director and Senior Analyst covering BioPharmaceuticals. Prior to joining Oppenheimer, Leland was Chief Financial Officer of Capricor Therapeutics and Tonix Pharmaceuticals. Leland also has both sell-side and buy-side experience and began his career on Cowen's biotechnology research team, where he provided sole coverage focused in the small and mid-cap segment. Leland has also authored numerous editorial and review articles and is an inventor on patents for Merck's Zolinza®. He earned his MD and Ph.D. in Organic Chemistry from Columbia University and his BA magna cum laude in Chemistry and Asian Studies from Dartmouth College.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
CRNX Crinetics Pharmaceuticals	9/30/2025	Boost Price Target	$41.47	$87.00	Outperform
TECX Tectonic Therapeutic	9/3/2025	Initiated Coverage	$16.65	$80.00	Outperform
VRDN Viridian Therapeutics	8/7/2025	Boost Price Target	$16.81	$32.00	Outperform
SLNO Soleno Therapeutics	8/7/2025	Boost Price Target	$80.36	$110.00	Outperform
BBIO BridgeBio Pharma	8/6/2025	Boost Price Target	$49.21	$61.00	Outperform
ALNY Alnylam Pharmaceuticals	8/4/2025	Upgrade	$401.80	$490.00	Outperform
LXEO Lexeo Therapeutics	7/31/2025	Initiated Coverage	$4.65	$20.00	Outperform
RYTM Rhythm Pharmaceuticals	7/10/2025	Boost Price Target	$88.42	$110.00	Outperform
BBIO BridgeBio Pharma	7/9/2025	Upgrade	$43.19	$60.00	Outperform
CAPR Capricor Therapeutics	6/23/2025	Lower Price Target	$7.15	$22.00	Outperform
URGN Urogen Pharma	6/13/2025	Set Price Target	$13.49	$31.00	Buy
ASND Ascendis Pharma A/S	6/13/2025	Reiterated Rating	$172.66	$224.00	Outperform
CLYM Climb Bio	6/6/2025	Initiated Coverage	$1.24	$10.00	Outperform
URGN Urogen Pharma	6/3/2025	Lower Price Target	$4.96	$10.00	Outperform
XERS Xeris Biopharma	5/9/2025	Boost Price Target	$5.07	$7.00	Outperform
ARGX argenex	5/9/2025	Boost Price Target	$554.89	$708.00	Outperform
QNCX Quince Therapeutics	3/24/2025	Initiated Coverage	$1.38	$10.00	Outperform
TRVI Trevi Therapeutics	3/11/2025	Boost Price Target	$5.87	$20.00	Outperform
ARGX argenex	2/28/2025	Boost Price Target	$619.04	$704.00	Outperform
BMRN BioMarin Pharmaceutical	2/24/2025	Upgrade	$68.25	$98.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.